Romark Laboratories, L.C. Selects DSG, Inc. For Influenza Study
Published: Mar 11, 2014
MALVERN, Pa.--(BUSINESS WIRE)--As influenza continues to lead to more than 226,000 hospitalizations and 24,000 deaths annually in the United States alone, new treatments are critical for fighting the latest strains of the virus. To combat this seasonal issue, Romark Laboratories will complete the advanced development of Nitazoxanide (NT-300) as a treatment for acute uncomplicated influenza in a Phase III clinical study using the integrated eClinical products and services from DSG.
Help employers find you! Check out all the jobs and post your resume.